McRae Capital Management’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $538K | Sell |
464
-1
| -0.2% | -$1.18K | 0.1% | 75 |
|
|
2026
Q2 | $557K | Buy |
465
+1
| +0.2% | +$1.02K | 0.11% | 67 |
|
|
2026
Q1 | $427K | Sell |
464
-34
| -7% | -$34.5K | 0.09% | 77 |
|
|
2025
Q4 | $535K | Sell |
498
-338
| -40% | -$323K | 0.11% | 64 |
|
|
2025
Q3 | $638K | Sell |
836
-100
| -11% | -$74.4K | 0.13% | 60 |
|
|
2025
Q2 | $730K | Sell |
936
-105
| -10% | -$81.6K | 0.15% | 54 |
|
|
2025
Q1 | $860K | Sell |
1,041
-20
| -2% | -$16.6K | 0.18% | 50 |
|
|
2024
Q4 | $819K | Sell |
1,061
-10
| -0.9% | -$8.28K | 0.16% | 50 |
|
|
2024
Q3 | $949K | Sell |
1,071
-50
| -4% | -$45K | 0.19% | 47 |
|
|
2024
Q2 | $1.01M | Hold |
1,121
| – | – | 0.23% | 42 |
|
|
2024
Q1 | $872K | Sell |
1,121
-110
| -9% | -$78.3K | 0.19% | 49 |
|
|
2023
Q4 | $718K | Hold |
1,231
| – | – | 0.18% | 52 |
|
|
2023
Q3 | $661K | Sell |
1,231
-165
| -12% | -$85K | 0.2% | 53 |
|
|
2023
Q2 | $655K | Sell |
1,396
-50
| -3% | -$21K | 0.19% | 51 |
|
|
2023
Q1 | $497K | Sell |
1,446
-190
| -12% | -$64.1K | 0.14% | 57 |
|
|
2022
Q4 | $599K | Sell |
1,636
-125
| -7% | -$44.3K | 0.18% | 56 |
|
|
2022
Q3 | $569K | Sell |
1,761
-844
| -32% | -$267K | 0.17% | 55 |
|
|
2022
Q2 | $845K | Buy |
2,605
+183
| +8% | +$54.9K | 0.23% | 47 |
|
|
2022
Q1 | $694K | Hold |
2,422
| – | – | 0.16% | 57 |
|
|
2021
Q4 | $669K | Sell |
2,422
-100
| -4% | -$25.4K | 0.14% | 57 |
|
|
2021
Q3 | $583K | Hold |
2,522
| – | – | 0.13% | 62 |
|
|
2021
Q2 | $579K | Hold |
2,522
| – | – | 0.13% | 61 |
|
|
2021
Q1 | $471K | Hold |
2,522
| – | – | 0.12% | 62 |
|
|
2020
Q4 | $426K | Buy |
2,522
+100
| +4% | +$14.9K | 0.12% | 63 |
|
|
2020
Q3 | $359K | Hold |
2,422
| – | – | 0.12% | 66 |
|
|
2020
Q2 | $398K | Sell |
2,422
-42
| -2% | -$6.45K | 0.15% | 62 |
|
|
2020
Q1 | $342K | Buy |
2,464
+342
| +16% | +$47K | 0.17% | 62 |
|
|
2019
Q4 | $279K | Hold |
2,122
| – | – | 0.1% | 78 |
|
|
2019
Q3 | $237K | Sell |
2,122
-532
| -20% | -$59.2K | 0.09% | 85 |
|
|
2019
Q2 | $294K | Hold |
2,654
| – | – | 0.12% | 72 |
|
|
2019
Q1 | $344K | Hold |
2,654
| – | – | 0.14% | 72 |
|
|
2018
Q4 | $307K | Hold |
2,654
| – | – | 0.16% | 70 |
|
|
2018
Q3 | $285K | Sell |
2,654
-100
| -4% | -$10K | 0.12% | 76 |
|
|
2018
Q2 | $235K | Hold |
2,754
| – | – | 0.1% | 87 |
|
|
2018
Q1 | $213K | Hold |
2,754
| – | – | 0.1% | 85 |
|
|
2017
Q4 | $233K | Sell |
2,754
-350
| -11% | -$29.8K | 0.1% | 84 |
|
|
2017
Q3 | $266K | Hold |
3,104
| – | – | 0.11% | 79 |
|
|
2017
Q2 | $255K | Hold |
3,104
| – | – | 0.1% | 84 |
|
|
2017
Q1 | $261K | Hold |
3,104
| – | – | 0.11% | 83 |
|
|
2016
Q4 | $228K | Hold |
3,104
| – | – | 0.1% | 89 |
|
|
2016
Q3 | $249K | Hold |
3,104
| – | – | 0.11% | 88 |
|
|
2016
Q2 | $244K | Buy |
+3,104
| New | +$234K | 0.11% | 89 |
|
Other funds holding LLY
PCA
McRae Capital Management's LLY Position: Q3 2026 in Review
McRae Capital Management reduced its Eli Lilly (LLY) stake by 0.22% in Q3 2026, selling an estimated $1.18K and leaving 464 shares worth $538K. The position accounts for 0.1% of the portfolio, ranked #75.
McRae Capital Management first reported a position in LLY in Q2 2016 and has held it in 42 quarters since. The position peaked at $1.01M in Q2 2024. 687 funds tracked by Wall St. Rank hold LLY as of Q3 2026.
- McRae Capital Management held 464 shares of Eli Lilly worth $538K as of Q3 2026.
- McRae Capital Management sold 1 Eli Lilly share in Q3 2026, an estimated $1.18K.
- Eli Lilly made up 0.1% of McRae Capital Management's portfolio in Q3 2026, its #75 holding.
- McRae Capital Management first reported a position in Eli Lilly in Q2 2016 and has held it in 42 quarters since.
- McRae Capital Management's Eli Lilly position peaked at $1.01M in Q2 2024.
- 687 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.
Based on McRae Capital Management's 13F filing for Q3 2026, filed 15 Oct 2026.